SCHEMBL17217283

SCHEMBL17217283

COc1cccc(CON=[C]c2ccc(Cl)cc2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 2/20 0.48
▸ AGXT P21549 2/20 0.48
▸ MAOB P27338 4/20 0.46
▸ LMNA P02545 3/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ HTT P42858 2/20 0.43
▸ GAA P10253 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ KCNA5 P22460 1/20 0.42
▸ CHRM2 P08172 1/20 0.42
▸ CHRM1 P11229 1/20 0.42
▸ CHRM3 P20309 1/20 0.42
▸ SLC6A4 P31645 1/20 0.42
▸ CNR1 P21554 1/20 0.42
▸ NPC1 O15118 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ TAAR1 Q96RJ0 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17217280 1.00 IDO1 (0.48) IDO1AGXTMAOBLMNASMN1; SMN2
SCHEMBL17217437 0.92 MAOB (0.54) IDO1AGXTMAOBSMN1; SMN2CHRM2
SCHEMBL17217434 0.92 MAOB (0.54) IDO1AGXTMAOBSMN1; SMN2CHRM2
SCHEMBL17216129 0.89 MAOB (0.49) IDO1AGXTMAOBLMNATP53
SCHEMBL17216132 0.89 MAOB (0.49) IDO1AGXTMAOBLMNATP53
SCHEMBL17217842 0.88 IDO1 (0.47) IDO1AGXTMAOBCHRM2CHRM1
SCHEMBL17217845 0.88 IDO1 (0.47) IDO1AGXTMAOBCHRM2CHRM1
SCHEMBL17217550 0.88 MAOB (0.49) IDO1AGXTMAOBCHRM2CHRM1
SCHEMBL17217547 0.88 MAOB (0.49) IDO1AGXTMAOBCHRM2CHRM1
SCHEMBL17215826 0.87 IDO1 (0.51) IDO1AGXTMAOBSMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2940012-B1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF SUMITOMO CHEMICAL CO (JP) 2019-01-30 — — EP disclosed
US-9560850-B2 Tetrazolinone compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-02-07 — — US disclosed
US-20150336908-A1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-11-26 — — US disclosed
EP-2940012-A1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF Sumitomo Chemical Company Limited (JP) 2015-11-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150336908-A1 TETRAZOLINONE COMPOUND AND USE THEREOF RTN3, CYP51A1, TCOF1 IDO1 2882/4885AGXT 1423/4885MAOB 3611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback